Form 4 Filing for Matthew L. Posard

Matthew L. Posard, a director at HALOZYME THERAPEUTICS, INC., reported the sale of 3100 shares of Common Stock on September 16, 2026, for an average price of $106.132 per share. The sale was part of a trading plan adopted in accordance with Rule 10b5-1. Following this transaction, Posard owns 74,735 shares. Additional sales occurred on the same day: 3000 shares at an average price of $106.828, 8896 shares at $108.04, and 4000 shares at $108.991. These transactions also were conducted under the Rule 10b5-1 trading plan. The weighted average prices are detailed, with specific price ranges provided for each transaction. The footnotes clarify the nature of the weighted average prices and the legal framework under which these sales were executed.